

Ref. No.: WOCK/SEC/SE/2026-27/016

4th June, 2026

BSE Limited Corporate Relations Department P J Towers Dalal Street Mumbai - 400 001 <u>Scrip Code: 532300</u>	National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai - 400 051 <u>NSE Symbol: WOCKPHARMA</u>
--	---

Dear Sir/ Madam,

Subject: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended – Investor Presentation

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and in continuation to our letter bearing reference no. Ref. No.: WOCK/SEC/SE/2026-27/015 dated 1st June, 2026, please find enclosed herewith a copy of the Investor Presentation to be made at the Investor Meeting scheduled to be held on 4th June, 2026.

The said Investor Presentation will also be uploaded on the Company's website and can be accessed through the following link:

<https://www.wockhardt.com/investors/analyst-investors/presentation/>

Kindly take the same on record please.

Thanking you,

For Wockhardt Limited

Rashmi Mamtura
Company Secretary

Encls: A/a



Innovation. Performance. Growth.

A Global Innovation-Led Healthcare Company



Novel Antibiotics



Pharmaceuticals



Biotechnology

Investor Conference | 04 June 2026

Disclaimer

This presentation contains “forward-looking statements” – that is, statements that relate to future, not past events or historical facts. All forward-looking statements are based on judgments derived from the information available to the company at this time. Forward-looking statements can be identified by terminology such as such as “potential,” “expected,” “will,” “planned,” or similar terms. Forward looking statements are based on the current beliefs and expectations of Wockhardt regarding future events, and are subject to various risks and uncertainties, many of which are difficult to predict. Actual results may differ materially from anticipated results. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. We do not undertake any obligation to update any forward-looking statement in this presentation, whether as a result of changes in underlying factors, new information, future events or otherwise. The information in this document have been collected with the purpose to provide interested parties with information about Wockhardt. The information is not comprehensive or complete and thus does not represent an adequate basis for a final decision about an investment. The presentation may not be copied, duplicated or transferred to third parties without the prior written approval of Wockhardt.

Agenda

- **Wockhardt's Strategic Overview and Growth drivers - Dr. Murtaza Khorakiwala (Managing Director)**
- **Foray of Zaynich in US - Zahabiya Khorakiwala (Director)**
- **Zaynich Strategy in India - Annapurna Das (President- India Business & NCE Emerging Markets)**
- **Q&A**

Agenda

- **Wockhardt's Strategic Overview and Growth drivers - Dr. Murtaza Khorakiwala (Managing Director)**
- Foray of Zaynich in US - Zahabiya Khorakiwala (Director)
- Zaynich Strategy in India - Annapurna Das (President- India Business & NCE Emerging Markets)
- Q&A

Overview & Business Performance

Global *Research - driven* multinational



Novel Antibiotics

World-leading discovery engine for first-in-class new chemical entities targeting antimicrobial resistance.




Biotechnology

Integrated diabetes-biosimilars franchise spanning human insulin and insulin analogues.



Pharmaceuticals

Branded and specialty pharmaceutical presence across India and global markets.



11 manufacturing facilities across globe



2 R&D centers one each in India, UK

Key Financials



INR 3,373 Cr.
FY26 Income



51%
Y-o-Y EBITDA growth¹



INR 630 Cr.
FY26 EBITDA



0.10
Net Debt : Equity ratio²



INR 238 Cr.
FY26 PBT



INR 662 Cr.
Cash & Cash Equivalents³

1. FY26 vs FY25
2. As on 31st March 2026, excluding promoter debt
3. As at 31st March 2026

Performance 01

Specialty Business growth

23%

Contribution to revenues of novel antibiotics & biosimilars

Emrok delivered strong growth of ~50%; Market leading anti-MRSA brand


27%

Biotech business growth

Production scale-up: 2x for Human Insulin & 1.5x for Glargine

Performance 02


Regional Business contribution



Regional contribution not to scale

Performance 03

Improved Profitability




Profitability Focus

- Margin Maximization**
 Focused on high-margin core products to maximise returns
- Supply Chain Optimization**
 Streamlined sourcing to build cost resilience
- Exit of US Generic Business**
 Divested underperforming US pharma generics business to sharpen portfolio focus


Performance 04

Operational Excellence



Manufacturing Re-structuring

Optimized plant capacity and footprint for efficiency gains



Cost Management

Drove systemic cost reduction through disciplined controls

- 50+ projects implemented
- AVD



Corporate-wide Improvements

Accelerated enterprise-wide transformation initiatives

- AI-led
- S4 HANA

Key Growth Drivers

Looking Ahead

Objectives for the next two years — growth acceleration, sustainable operational excellence enabled by AI

01

Novel Antibiotics



- Launch Zaynich in the US, India, Europe and EM
- Miqnaf: Extending reach & additional indications
- Emrok & Emrok O: strengthening franchise

03

Pharma Business



- EU growth
- Accelerating India business

02

Biotech Business Accelerator



- Enhanced biotech capacity to address surge in insulin demand
- Deeper diabetes biosimilars pipeline

04


Operational Excellence 2.0



- People: New capabilities & talent
- AI-enabled operational excellence initiatives
- Sustainability and scalability

Growth 02/04

Biosimilar Diabetes Franchise



Growth 02/04

Biosimilars portfolio and end-to-end platform

Integrated capabilities from lab to patient — a comprehensive pipeline across Human Insulin and insulin analogs

2

Commercialized products

Recombinant Insulin & Glargine

5

Pipeline assets

R&D through Phase III

30+

Emerging markets

Registered & actively supplied



Patented delivery devices (pen)



Vials



Cartridges

Pipeline Across Human Insulin & Insulin Analogs

Recombinant Human Insulin	Commercialized
---------------------------	----------------

Glargine	Commercialized
----------	----------------

Aspart R	Phase III
----------	-----------

Aspart 30/70	PK/PD study
--------------	-------------

Degludec	R&D
----------	-----

Degludec + Aspart	R&D
-------------------	-----

Semaglutide	R&D
-------------	-----

Growth 03/04

Pharma Portfolio

India



Diabetes Portfolio: Market penetration



Ortho & Pain: New launches



Regenerative: Growth



Trade & Quality Generics: Rapid portfolio expansion

UK



18% covered market share



Hospital, Pharmacy & Export segment



8 Filings



5 Approvals



8 New launches

Pinewood



Market leadership-
Methadone, Pinamox,
Codeine, Flucillin, Cortopin



7 Filings



8 Approval



15 New launches

The Wockhardt Journey



Agenda

- Wockhardt's Strategic Overview and Growth drivers - Dr. Murtaza Khorakiwala (Managing Director)
- **Foray of Zaynich in US - Zahabiya Khorakiwala (Director)**
- Zaynich Strategy in India - Annapurna Das (President- India Business & NCE Emerging Markets)
- Q&A

Zaynich™ Approved by US FDA

First Indian discovered drug from **lab bench to approval** that catapults **India** in the **Global spotlight**



**Indian Origin
discovery**




Best in Class



Global Impact

USA: Commercial opportunity

~1.2 Million Gram-negative Hospital Infections in USA



Sources: Evaluation by Independent agency

Clinical Development

Treatment failures combined with limited alternatives create a meaningful opportunity for Zaynich™

~40%

Treatment failure rates for empiric therapy due to carbapenem resistance in high burden settings for cUTI patients

15-25%

Polymicrobial infection complicates therapy selection

3-5x

Higher hospitalization risk in elderly, thereby bearing disproportionate morbidity

20-25%

High infection recurrence increases hospitalizations and re-admissions



Limited coverage options for all pathogens & resistance mechanisms

Zaynich™ tackles pan drug-resistant infections riding on its unique mechanism of action



**Kills major
Carbapenem resistant
bacteria that other
drug fails to treat**

Broader coverage
compared with other
treatment options



**Targeting multiple
penicillin binding
protein mechanism of
action**

Unlike classical BLI,
Zidebactam binds to PBP2
causing bacterial cell death



**Established Safety
Profile**

Safe for patients with
multiple co-morbidities
with minimal drug
interactions

Clinical Development

Zaynich™ is a novel antibiotic for Gram-negative infections coupled with a strong safety profile



Clinical Cure Rate in Global Phase III



Clinical + Microbiological Cure Rate in Phase III

20% higher composite cure vs standard of the care, Meropenem



Clinical Efficacy in Phase II CRO Study



Compassionate use patients cured from highly resistant infections

Capabilities Development

Leadership on boarded for commercialization of Zaynich



William McNey
Chief Commercial Officer

Experience: 25+ years
Previous Organizations: IQVIA, Invivyd, Shionogi, PwC, Novartis, GSK, and Dey Pharma



Dr. Dennis Deruelle
Chief Medical Officer

Experience: 19+ years
Previous Organizations: Vitasora Health, NeuroSensa, Mendota Health, TeamHealth, American Physician Partners, and IPC



Leo Yasinski
Vice President – Market Access

Experience: 20+ years
Previous Organizations: Innoviva, La Jolla, Tetrphase Pharmaceuticals, Merck & Co., Cubist Pharmaceuticals, and Wyeth Pharmaceuticals



Sandy Estrada
Field Medical Affairs

Experience: 20+ years
Previous Organizations: CorMedix Therapeutics, Melinta Therapeutics, Heron Therapeutics, T2Biosystems, Lee Memorial Health System

Launch excellence

Strategy to established a “competency & capability heavy, but operationally light” integrated launch architecture

 **Wockhardt USA Leadership team to drive strategy & execution**



Strong **market access** for wide penetration




HEOR: showcasing economic benefit of Zaynich to hospital system to lower re-admission rates & average length of stay



Clinical advocacy building on the strong relationship with KOLs through ad-boards



Deployment: Medical Science Liaison, Market Access, Sales & Marketing



Logistics: trade & distribution partnership (3PL) secured



Secured Global Supply Chain: Manufacturing from US FDA approved European site

Overarching strategy to maximize hospital penetration & clinician adoption


Agenda

- Wockhardt's Strategic Overview and Growth drivers - Dr. Murtaza Khorakiwala (Managing Director)
- Foray of Zaynich in US - Zahabiya Khorakiwala (Director)
- **Zaynich Strategy in India - Annapurna Das (President- India Business & NCE Emerging Markets)**
- Q&A

Zaynich[®] Approved by CDSCO, India

India: Burden

India's Carbapenem Resistance Burden : Rising CR cases and resistance trends is a reality with improving healthcare access



Organism	CR Rate (India)	Trend
<i>Klebsiella pneumoniae</i>	~52-70%	↑ Rising
<i>Acinetobacter baumannii</i>	~60-80%	Stable High
<i>Pseudomonas aeruginosa</i>	~25-40%	↑ Rising
<i>Escherichia coli</i>	~8-15%	↑ Rising

Sources: ICMR-AMR Annual Report 2022, WHO GLASS India Data 2021-23

It takes *2–10 years* for innovation to reach Emerging Markets.
We want to break the cycle.

Challenge the
conventional

Launch Playbook

India: Launch Plan 1/2 

Zaynich Launch Priorities

Building Real world evidence (RWE) and driving **right usage in right patients** is not an option - it is the strategy

Drive Accelerated Market Penetration

Build Go-To-Market (Share of Voice & Reach) for $\geq 80\%$ patient pool coverage

Physician Experience Building | RWE & Hospitals / Physicians engagement

Maximize Patient Impact : Alleviate Price as Access Barrier and drive Right Usage

Tiered access centric pricing across public \leftrightarrow private delivery chains to drive stewardship

PRECISION ANTIBIOTIC STEWARDSHIP | Standard of Care (SoC) · Mitigate Over & Under-usage

Shape AMR Management Ecosystem

Patient-centric standards across HCPs, Regulators & Policy Makers

MULTI-STAKEHOLDER PARTNERSHIPS | AMR Management Excellence

India: Launch Plan 2/2

India Patient Access Approach

CR Burden Led Access for Patient Pool in Private and Public



PUBLIC · Access for Public Payors including States

EM Disease Landscape

Carbapenem Resistance Burden in Emerging Markets

~ 1.5 Mn+ CR cases in EM markets · High unmet need for managing CR organism infections

~1.5Mn+

Estimated CR cases per year across EM's

- Resistance is rising rapidly across EM markets — outpacing treatment options

~10% to 40%

Resistance rates across key EM's

- Multiple resistance mechanisms make infections **Hard-to-Treat or Difficult-to-Treat**
- Standard antibiotics increasingly fail ; creating urgent unmet clinical need

\$3-4 Bn

Addressable market size

Enter 7-8 Key Markets with high CR burden in next 18-24 months


Aim for Registration & Launch:

Latin America, Eurasia, GCC and South / South East Asia markets

INDIA & EM a Multiplier , Not Additive

Market potential :
Patient Pool

Industry-leading
Launch : Patient
Access



Building patient centric
business and operating model
delivering sizeable,
sustainable and profitable
revenue

Millions of patients in Emerging Markets are waiting for the right antibiotic.

Every day without access is a life at risk from carbapenem-resistant infections.



Abbreviations

®: Registered

~: Approximate

AMR: Anti Microbial Resistance

Bn: Billion

BLI: Beta Lactamase Inhibitor

CDSCO: Central Drugs Standard Control Organization

CRO: Carbapenem Resistant Organism

cUTI : Complicated urinary tract

Infections

Cr.: Crore

EBITDA : Earnings before interest, taxes, depreciation, and amortization

HABP: Hospital Acquired Bacterial Pneumonia

ICMR: Indian Council of Medical Research

INR: Indian rupee

KOL: Key opinion leader

LCM: Life cycle management

MRSA: Methicillin-resistant Staphylococcus aureus

Mn – Million

NCE: New chemical entity

PBP: Penicillin-binding proteins

R&D: Research and Development

RWE: Real world evidence

TM: Trademark

UK: United Kingdom

US: United States

US-FDA: United States Food and Drug Administration

VABP: Ventilator Acquired Bacterial Pneumonia

Y-o-Y: Year-over-year